By Darrin LaVelle, Founder of RENVA Health
Last updated: July 3, 2026
Short answer: nausea and other digestive symptoms affect a large share of people starting GLP-1 medications — roughly 3 to 4 in 10, depending on the drug and dose — and these are usually most intense early on and improve over time. Serious complications are documented but uncommon. Here's what the actual data shows, not just the headline warnings.
Every GLP-1 medication comes with a long list of possible side effects on the label, which can make it hard to tell what's actually likely to happen to you versus what's a rare, worst-case scenario. This breaks down both — the common, expected symptoms and the rare but serious ones — using FDA labeling and real-world adverse event data.
This is, by a wide margin, the main category of side effect for every GLP-1 and dual-agonist medication currently approved.
FDA labeling lists the most common side effects (occurring in 5% or more of patients) as nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion, dizziness, bloating, belching, low blood sugar (in people with diabetes), gas, and heartburn. In trials, nausea specifically was reported in roughly 40–44% of people on the medication, depending on dose — a substantial share, though most cases were mild to moderate rather than severe.
Zepbound's label lists a similar core group: nausea, diarrhea, vomiting, constipation, abdominal pain, injection-site reactions, fatigue, hypersensitivity reactions, hair loss, and heartburn. In the SURMOUNT-1 trial, gastrointestinal side effects overall occurred in 30–40% of participants, with nausea again being the single most common individual symptom — generally a somewhat lower rate than what's reported for semaglutide, though both drugs share the same basic symptom profile.
These symptoms aren't random — they're a direct consequence of how the medications work. GLP-1 and dual GIP/GLP-1 agonists deliberately slow down stomach emptying and intestinal movement as part of how they create fullness and reduce appetite. That same slowing is what produces nausea, bloating, and reflux in many people. On top of that, these medications can shift food preferences and cause aversions to foods — particularly high-fat foods — that were previously enjoyed without issue, which can itself trigger nausea if those foods are eaten anyway.
Across the labeling and clinical trial data, GI side effects follow a consistent pattern: they show up most intensely during the first 8 to 12 weeks — specifically during dose escalation — and tend to decrease as the body adjusts to each dose level. This is actually the entire reason the titration schedules for both drugs start low and increase gradually: it's a deliberate design choice to reduce the severity of these exact symptoms, not an arbitrary bureaucratic delay.
Based on clinical guidance and prescribing information, a few practical approaches are commonly recommended:
If GI symptoms become severe, prescribers may hold a dose or reduce it temporarily — this is a normal part of managing treatment, not a sign that something has gone wrong or that you need to stop altogether.
Beyond the GI symptoms, both medications carry warnings for more serious, though considerably less common, complications.
Both Wegovy and Zepbound carry the FDA's most serious type of warning — a boxed warning — for thyroid C-cell tumors, based on findings in rodent studies where these drugs caused thyroid tumors at high doses. Because of this, both medications are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It's worth noting that the human relevance of the rodent findings remains genuinely uncertain — long-term human monitoring hasn't shown a clear causal link to thyroid cancer in people, but the warning and the contraindication remain in place out of caution.
Both drugs' labels warn about acute pancreatitis, with instructions to seek immediate medical care for severe abdominal pain — especially pain that radiates to the back, with or without vomiting. Some post-marketing reports have linked GLP-1 medications to pancreatitis, though a definitive causal relationship hasn't been established.
Gallstones and gallbladder inflammation are also called out in both labels. This connection isn't entirely about the drug itself — rapid weight loss of any kind, from any cause, increases gallstone risk, and GLP-1-driven weight loss is no exception. Some trial participants have needed gallbladder removal during treatment.
Beyond the thyroid-related contraindications above, these medications aren't recommended for anyone with severe gastroparesis (a condition that already delays stomach emptying), since the drugs' own effect on gastric emptying could worsen those symptoms.
Beyond clinical trials, regulators track real-world side effect reports through a system called FAERS (FDA Adverse Event Reporting System). A few things stand out from recent analyses of that data:
It's worth keeping this kind of data in perspective: FAERS reports are voluntary and don't prove that a medication caused a given event — they're a monitoring tool, not a diagnosis. But the scale of reporting does reflect how widely these medications are now being used, and regulators continue to track patterns as that usage grows.
Separately, poison control centers have documented a sharp rise in calls related to GLP-1 medications in recent years — the vast majority involving accidental dosing errors (like taking doses too close together, or confusion around compounded product dosing units) rather than intentional misuse. This underscores something worth taking seriously regardless of which GLP-1 medication you're on: understanding exactly how to measure and administer your specific dose, and asking your provider or pharmacist directly if anything about your prescription's dosing instructions is unclear.
One aspect of GLP-1 treatment that gets less attention than nausea or pancreatitis is body composition — specifically, that not all the weight lost on these medications is fat.
A 2025 review of body composition data across multiple obesity trials found that roughly 20–40% of total weight lost with GLP-1 and dual-agonist medications was lean tissue (muscle), not fat — the exact proportion varying by drug and dose. The same review noted that most of the weight lost is still fat, but the lean tissue loss is real and clinically meaningful, and appears to be more pronounced in older adults and those already at risk of age-related muscle loss.
Obesity and geriatric medicine specialists generally interpret this as a reason to pair GLP-1 treatment with resistance exercise and adequate protein intake — not to offset the medication's effect on appetite, but specifically to help preserve muscle mass and physical function while the medication does its work on fat loss. This is particularly relevant for older adults, where muscle preservation has direct implications for long-term mobility and independence.
Q: Is nausea inevitable on these medications?
No — it's common but not universal. Roughly 3 to 4 in 10 people experience it, meaning a majority don't, or experience it only mildly.
Q: Does nausea ever fully go away?
For most people, yes — it tends to peak during dose increases and improve as the body adjusts to each new dose level, though some people continue to notice mild symptoms at higher maintenance doses.
Q: How worried should I be about thyroid cancer risk?
The boxed warning is based on rodent studies, and its relevance to humans remains uncertain based on available long-term data. The contraindication exists specifically for people with a personal or family history of medullary thyroid carcinoma or MEN 2 — if that doesn't apply to you, this is a risk category worth understanding but not one with confirmed human evidence behind it.
Q: Will I lose muscle along with fat?
Some lean tissue loss is documented across trials, typically representing a meaningful minority of total weight lost. Resistance exercise and sufficient protein intake during treatment are commonly recommended to help offset this.
Q: What should I do if I have severe abdominal pain?
Seek medical care promptly, particularly if the pain is severe or radiates to your back — this combination is specifically called out in prescribing information as a possible sign of pancreatitis that needs immediate evaluation.
See also: Muscle Loss on GLP-1 Medications for a deeper look at body composition during treatment and what helps protect lean mass, and How Long Does It Take for GLP-1 Medications to Work? for the full week-by-week progression including when side effects typically peak.
Medical disclaimer: RENVA is not a healthcare provider. This article is informational and educational only. It does not constitute medical advice, diagnosis, or a prescription. Always consult a licensed healthcare professional before making health decisions. Full medical disclaimer →
Answer a few preference questions — budget, labs, provider model, and cancellation flexibility. Preference-based and informational only.
Take the free quizGLP-1 medications explained in plain language: what they are, how they work in your gut and brain, and what the research shows about weight loss results.
GLP-1 medications start affecting appetite within days, but meaningful weight loss builds over months. Here's the actual week-by-week timeline from clinical trial data.
Research on stopping GLP-1 medications shows most people regain a significant share of lost weight. Here's what the data actually shows and why it happens.